HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 80.1%

Neg 0% Neu 0% Pos 80.1%

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and raises the price target from $9 to $11.